Skip to main
EMBC

Embecta Corp (EMBC) Stock Forecast & Price Target

Embecta Corp (EMBC) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 33%
Buy 0%
Hold 33%
Sell 33%
Strong Sell 0%

Bulls say

Embecta is facing challenges in its core market, particularly in the U.S., leading to reduced profitability and a revision of its capital allocation priorities. However, its efforts to transition into a broader medical device company and add sales growth may still take shape if the core market stabilizes. The company's revenue and earnings are expected to decline in the near term, with limited visibility for improvement. Despite these challenges, the company has a strong portfolio of products and a leading position in the market, and trades at a discount to its peers.

Bears say

Embecta is a medical device company with a diverse portfolio of products aimed at helping patients with diabetes. Despite its market leadership and global presence, the company has recently faced challenges in the US market, leading to a significant decline in its profitability outlook. This, coupled with the uncertainties surrounding future headwinds and commercial execution, has resulted in a negative outlook for the company's stock.

Embecta Corp (EMBC) has been analyzed by 3 analysts, with a consensus rating of Hold. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 33% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Embecta Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Embecta Corp (EMBC) Forecast

Analysts have given Embecta Corp (EMBC) a Hold based on their latest research and market trends.

According to 3 analysts, Embecta Corp (EMBC) has a Hold consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Embecta Corp (EMBC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.